NASDAQ:IOBT IO Biotech (IOBT) Stock Forecast, Price & News $1.47 +0.06 (+4.26%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.39▼$1.4850-Day Range$1.39▼$2.0352-Week Range$1.35▼$3.52Volume34,766 shsAverage Volume187,440 shsMarket Capitalization$96.84 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IO Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside410.2% Upside$7.50 Price TargetShort InterestHealthy3.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$6 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.21) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector559th out of 965 stocksPharmaceutical Preparations Industry258th out of 456 stocks 3.5 Analyst's Opinion Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, IO Biotech has a forecasted upside of 410.2% from its current price of $1.47.Amount of Analyst CoverageIO Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.59% of the float of IO Biotech has been sold short.Short Interest Ratio / Days to CoverIO Biotech has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IO Biotech has recently increased by 15.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIO Biotech does not currently pay a dividend.Dividend GrowthIO Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IOBT. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 3 people have searched for IOBT on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows5 people have added IO Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IO Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,999,999.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of IO Biotech is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for IO Biotech are expected to grow in the coming year, from ($2.21) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IO Biotech is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IO Biotech is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIO Biotech has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IO Biotech (NASDAQ:IOBT) StockIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Read More IOBT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOBT Stock News HeadlinesSeptember 15, 2023 | americanbankingnews.comIO Biotech's (IOBT) Buy Rating Reiterated at HC WainwrightSeptember 13, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on IO Biotech (IOBT)September 24, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 12, 2023 | finance.yahoo.comIO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung CancerSeptember 6, 2023 | finance.yahoo.comIO Biotech Announces Participation in Upcoming Investor ConferencesAugust 17, 2023 | finance.yahoo.comStonepine Capital Management, LLC Acquires New Stake in IO Biotech IncAugust 17, 2023 | finance.yahoo.com10 Best New Penny Stocks to Buy NowAugust 15, 2023 | msn.comMorgan Stanley Maintains IO Biotech (IOBT) Overweight RecommendationSeptember 24, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 12, 2023 | msn.comHC Wainwright & Co. Reiterates IO Biotech (IOBT) Buy RecommendationAugust 11, 2023 | markets.businessinsider.comIO Biotech (IOBT) Gets a Buy from H.C. WainwrightAugust 11, 2023 | finance.yahoo.comIO Biotech Appoints Heidi Hunter to its Board of DirectorsAugust 11, 2023 | finance.yahoo.comIO Biotech Announces 2023 Second Quarter ResultsAugust 8, 2023 | finance.yahoo.comIO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023August 7, 2023 | finance.yahoo.comIO Biotech, Inc. Announces $75 Million Private Placement FinancingJuly 28, 2023 | finance.yahoo.comIO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer CenterJuly 25, 2023 | finance.yahoo.comIO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung CancerJuly 18, 2023 | finance.yahoo.comIO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical OfficerJune 15, 2023 | finance.yahoo.com2 “Strong Buy” Penny Stocks That Could Rally Over 300%June 14, 2023 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on IO Biotech (IOBT)June 14, 2023 | finance.yahoo.comWhy Are IO Biotech Shares Trading Lower TodayJune 14, 2023 | finance.yahoo.comIO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment MilestoneJune 1, 2023 | finance.yahoo.comIO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program LeadMay 25, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on IO Biotech (IOBT)May 13, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on IO Biotech (IOBT)May 11, 2023 | seekingalpha.comIO Biotech GAAP EPS of -$0.59 beats by $0.09May 11, 2023 | finance.yahoo.comIO Biotech Announces 2023 First-Quarter ResultsSee More Headlines Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address IOBT Company Calendar Last Earnings8/11/2023Today9/24/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOBT CUSIPN/A CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$8.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+410.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.98% Return on Assets-52.24% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.82 per share Price / Book0.30Miscellaneous Outstanding Shares65,880,000Free Float63,575,000Market Cap$96.84 million OptionableNot Optionable Beta-0.64 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Mai-Britt Zocca Ph.D. (Age 55)Founder, Pres, CEO, Principal Financial Officer & Director Comp: $733.88kMs. Amy B. Sullivan M.B.A. (Age 53)Chief Financial Officer Comp: $391.24kProf. Inge Marie Svane M.D.Ph.D., Founder & Clinical AdvisorProf. Mads Hald Andersen M.D.Ph.D., Founder & Scientific AdvisorAnders LjungqvistFounderProf. Per Thor StratenFounderMr. Brian Burkavage (Age 39)Chief Accounting Officer Mr. Eric Faulkner M.B.A.Chief Technical OfficerMr. Devin Whittemore Smith (Age 55)Sec., Gen. Counsel & Chief Compliance Officer Mr. Daniel G. Mannix Ph.D.Sr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAIWerewolf TherapeuticsNASDAQ:HOWLGlycoMimeticsNASDAQ:GLYCBriaCell TherapeuticsNASDAQ:BCTXCytomX TherapeuticsNASDAQ:CTMXView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 9,152 shares on 8/15/2023Ownership: 0.131%Two Sigma Securities LLCBought 13,020 shares on 8/14/2023Ownership: 0.045%Renaissance Technologies LLCBought 7,400 shares on 8/11/2023Ownership: 0.240%Vivo Capital Ix, LlcBought 3,157,894 shares on 8/9/2023Total: $6.00 M ($1.90/share)Summit Trail Advisors LLCBought 43,744 shares on 7/25/2023Ownership: 0.152%View All Insider TransactionsView All Institutional Transactions IOBT Stock - Frequently Asked Questions Should I buy or sell IO Biotech stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOBT shares. View IOBT analyst ratings or view top-rated stocks. What is IO Biotech's stock price forecast for 2023? 2 Wall Street research analysts have issued 1 year price targets for IO Biotech's shares. Their IOBT share price forecasts range from $7.00 to $8.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 410.2% from the stock's current price. View analysts price targets for IOBT or view top-rated stocks among Wall Street analysts. How have IOBT shares performed in 2023? IO Biotech's stock was trading at $2.30 at the beginning of the year. Since then, IOBT stock has decreased by 36.1% and is now trading at $1.47. View the best growth stocks for 2023 here. Are investors shorting IO Biotech? IO Biotech saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 631,700 shares, an increase of 15.5% from the August 15th total of 546,900 shares. Based on an average daily trading volume, of 212,300 shares, the short-interest ratio is currently 3.0 days. Approximately 3.6% of the company's shares are short sold. View IO Biotech's Short Interest. When is IO Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our IOBT earnings forecast. How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.08. When did IO Biotech IPO? (IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share. What is IO Biotech's stock symbol? IO Biotech trades on the NASDAQ under the ticker symbol "IOBT." Who are IO Biotech's major shareholders? IO Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.24%), Summit Trail Advisors LLC (0.15%), Citadel Advisors LLC (0.13%) and Two Sigma Securities LLC (0.05%). Insiders that own company stock include Amy Sullivan and Vivo Capital Ix, Llc. View institutional ownership trends. How do I buy shares of IO Biotech? Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IO Biotech's stock price today? One share of IOBT stock can currently be purchased for approximately $1.47. How much money does IO Biotech make? IO Biotech (NASDAQ:IOBT) has a market capitalization of $96.84 million. The company earns $-71,460,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. How can I contact IO Biotech? The official website for the company is www.iobiotech.com. The company can be reached via phone at 45-7070-2980 or via email at mci@iobiotech.com. This page (NASDAQ:IOBT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.